Yearly Archives: 2025

SciTech Development Strengthens Leadership Team with Appointment of Dr. Peter Littrup as Medical Director and Joseph Kraus to Advisory Board

SciTech Development Strengthens Leadership Team with Appointment of Dr. Peter Littrup as Medical Director and Joseph Kraus to Advisory Board NEWS PROVIDED BY SciTech Development, Inc. Oct 21, 2025, 09:00 ET New appointments bolster clinical and financial leadership as SciTech advances its Series A financing and oncology trial expansion.   DETROIT, Oct. 21, 2025 /PRNewswire/…

SciTech Development Announces the Closing of Oversubscribed $5.5 Million Funding Round to Continue Cancer Clinical Trials

SciTech Development Announces the Closing of Oversubscribed $5.5 Million Funding Round to Continue Cancer Clinical Trials NEWS PROVIDED BY SciTech Development, Inc. Sep 24, 2025, 09:00 ET Investor confidence is fueled by remarkable interim clinical trial results for its drug, ST-001 nanoFenretinide™, showing 100% disease control at higher dose levels.   DETROIT, Sept. 24, 2025…

SciTech Second Quarterly 2025 Newsletter

SciTech Second Quarterly 2025 Newsletter NEWS PROVIDED BY SciTech Development 11 Jun, 2025, 09:00 ET DETROIT, Jun. 11, 2025 — Read the latest Second Quarterly 2025 newsletter here.  This captures all the updates including strong early data in T-cell lymphoma, FDA approval on our second IND for small cell lung cancer trial, expanded manufacturing, $20M Series A launch,…

2025 American Society of Clinical Oncology (ASCO) Annual Meeting Poster Presentation: ST-001 nanoFenretinide™ Trial in Patients with T-cell Non-Hodgkin Lymphoma

2025 American Society of Clinical Oncology (ASCO) Annual Meeting Poster Presentation: ST-001 nanoFenretinide™ Trial in Patients with T-cell Non-Hodgkin Lymphoma NEWS PROVIDED BY SciTech Development 05 Jun, 2025, 09:00 ET CHICAGO, Jun. 5, 2025 — SciTech Development presented a poster at the June 2025 American Society of Clinical Oncology (ASCO) meeting in Chicago, showcasing the…

SciTech Development Announces 2nd FDA Approval of a Phase 1 a/b IND For ST-001. New IND Targets the Treatment of Relapsed/Refractory Small Cell Lung Cancer Following Its Previous Approval in the Treatment of T-Cell NHL

SciTech Development Announces 2nd FDA Approval of a Phase 1 a/b IND For ST-001. New IND Targets the Treatment of Relapsed/Refractory Small Cell Lung Cancer Following Its Previous Approval in the Treatment of T-Cell NHL NEWS PROVIDED BY SciTech Development, Inc. Apr 08, 2025, 09:00 ET GROSSE POINTE FARMS, Mich., April 8, 2025 /PRNewswire/ –…

SciTech Development Advances to Next Stage of Clinical Trial for ST-001 nanoFenretinide™

SciTech Development Advances to Next Stage of Clinical Trial for ST-001 nanoFenretinide™ NEWS PROVIDED BY SciTech Development 13 Jan, 2025, 09:00 ET **Encouraging Data from Accelerated Trial Supports Progress for T-cell Non-Hodgkin Lymphoma.**   DETROIT, Jan. 13, 2025 /PRNewswire/ — SciTech Development, a clinical-stage pharmaceutical company specializing in oncology, is pleased to announce the initiation…